Esmeralda Campos-Aguirre, Julio César Martínez-Álvarez, María Araceli Arrazola-García, Oscar David Arroyo-García, María Guadalupe Delgado-Colín, Miguel Ángel Chávez-Durán, Alexis Ignacio Galván-Bobadilla, Gamaliel Benítez-Arvizu
Author Information
Esmeralda Campos-Aguirre: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
Julio César Martínez-Álvarez: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
María Araceli Arrazola-García: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
Oscar David Arroyo-García: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
María Guadalupe Delgado-Colín: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
Miguel Ángel Chávez-Durán: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
Alexis Ignacio Galván-Bobadilla: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
Gamaliel Benítez-Arvizu: Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México. ORCID
Background: Since the beginning of the SARS-CoV-2 pandemic, identifying the COVID-19 pathophysiology not only has been addressed to applying diagnostic tests or preventing through vaccines, but also to the timely detection, especially of patients in risk groups such as those in transplants areas (renal, hematology, etcetera). In the case of these patients, using RT-PCR tests avoids putting them at risk by subjecting them to states of immunosuppression that could aggravate their situation if they were faced with an onset of a COVID-19 infection. Objective: To present the results of patients of a transplant unit tested for SARS-CoV-2. Material and methods: Descriptive, observational, cross-sectional, and retrolective study. Data of results of RT-PCR tests of patients who underwent transplantation from June 2021 to April 2022 in a third level hospital were collected. Results: 755 tests were done to patients who underwent transplantation. 384 (50.8%) were women. Out of all patients, only 73 (9.7%) were positive to SARS-CoV-2. Conclusions: Implementing RT-PCR tests as a transplant protocol to detect SARS-CoV-2 prevents fatal complications due to COVID infection to donors and receptors.
